A paradigm shift in
cellular-based therapy
for regenerative medicine
Our platform technologies Progenza™ and Sygenus are novel approaches to pain, that leverage stem cells as cellular pharmacies and utilise Secretome as a therapeutic agent.
Q&A with Flyn McKinnirey, R&D Manager at Regeneus
Q. What is your background and experience in the regenerative medicine and stem cell space? How did this lead you to Regeneus? A. I’d always had a love for medical research, however found myself working in the pharmaceutical industry after university prior to joining Regeneus. After 6 years in the…
Q&A with Dr. Cindy Shu, REDI Fellow
After being awarded the MTPConnect REDI Fellowship Grant in August 2020, Postdoctoral Research Fellow from the Kolling Institute and University of Sydney Royal North Shore Hospital, Dr. Cindy Shu is joining Regeneus for a 12-month project focused on readying Progenza™ for Phase II trials in Japan…
Watch: Regeneus (ASX:RGS) Investor Update – November 2021
Regeneus CEO Karolis Rosickas hosted a webinar and Q&A with investors on Thursday 4 November. During the session, Karolis provided an update on the Company's progress with its lead platform technology Progenza™, partnership with the Australian Department of Defence for Sygenus, and ongoing…
Regeneus partners with ASTEM to improve efficiencies in adipose tissue donor selection
Regeneus has partnered with the Allogeneic STEM cell manufacturing Programme (ASTEM) to investigate the status of a novel genomic biomarker within their adipose donor banks. This work is being conducted at one of the partner institutes of the ASTEM Programme, the Genome Institute of Singapore,…
Regeneus in TechInvest
In July, Regeneus CEO Karolis Rosickas contributed an article to TechInvest Magazine – a quarterly publication for the tech and innovation sector featured in The Australian Financial Review. In an article titled 'For a life free of pain', Karolis Rosickas explains how Regeneus is potentially one…
The Science
MSCs and Secretome are the next frontier in targeting pain and inflammation. They combine to make a 'bioactive soup' that repurposes inflamed tissue at a site of injury, helping reduce pain and further tissue damage.
Product Pipeline
Our platform technologies Progenza™ and Sygenus represent a potential major paradigm shift in treating pain and inflammation at its source, by harnessing the power of MSCs and Secretome.
IP and Manufacturing
Our manufacturing techniques ensure cost-effective and high batch-to-batch consistency in our stem cell production. Alongside our research partners, we can scale up our platform technologies to meet market demand.
Partnering with us
Regeneus is constantly looking for partners and research collaborators.
Contact us for more information.